INNOVENT BIO (01801) announced that for the first quarter of 2026, the company achieved product revenue of more than RMB 3.8 billion, representing a year-on-year increase of over 50%. This robust performance demonstrates the successful execution of the company's "dual-engine" growth strategy. The company's leading position in the oncology field has become increasingly prominent, with five tyrosine kinase inhibitors (TKIs) experiencing rapid sales expansion following their recent inclusion in the National Reimbursement Drug List (NRDL). Concurrently, the comprehensive product portfolio has emerged as a powerful new driver of revenue growth, primarily fueled by the outstanding performance of core products such as Xelmei® (Mazdutide Injection), Xinbile® (Tolecimab Injection), and Xinbimin® (Tituyou Monoclonal Antibody N01 Injection). The strong results in Q1 2026 have bolstered confidence in the company's ability to sustain rapid revenue growth, further solidifying its profile as a high-growth and highly promising leading biopharmaceutical company in China. At the same time, the company is steadily advancing its global innovation initiatives, creating sustained upward potential for its value. It is currently progressing three high-value potential molecules—IBI363 (a PD-1/IL-2α-biased bispecific antibody), IBI343 (a CLDN18.2 ADC), and IBI324 (a VEGF/ANG2 bispecific antibody)—into or towards global multi-center Phase III clinical studies. The company continues to bolster its early-stage innovation efforts, driving the global clinical development of next-generation pipelines in oncology, cardiovascular and metabolic diseases (CVM), autoimmune disorders, and ophthalmology. Looking ahead, the continued solid expansion of its domestic business scale, coupled with the accelerated advancement of its global innovation pipeline, will steadily propel the company towards realizing its long-term vision of "becoming a world-class biopharmaceutical company."